里昂发表报告指,三生制药(01530.HK) 日前公布,与辉瑞(PFE.US) 就其突破性PD-1/VEGF双特异性抗体(SSGJ-707)达成中国以外的全球许可转让合作。该行认为,与过去类似的授权项目相比,是次授权的条款对三生制药更有利,因为康方生物(09926.HK) 的AK112在国内获得批准后,该资产的风险已大幅降低;又指辉瑞丰富的ADC资产组合,有助释放SSGJ-707作为ADC联合...
Source Link里昂发表报告指,三生制药(01530.HK) 日前公布,与辉瑞(PFE.US) 就其突破性PD-1/VEGF双特异性抗体(SSGJ-707)达成中国以外的全球许可转让合作。该行认为,与过去类似的授权项目相比,是次授权的条款对三生制药更有利,因为康方生物(09926.HK) 的AK112在国内获得批准后,该资产的风险已大幅降低;又指辉瑞丰富的ADC资产组合,有助释放SSGJ-707作为ADC联合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.